Basal Cell Adenoma and Basal Cell Adenocarcinoma: a 50-year Experience From a Single Institution

Head Neck Pathol. 2022 Dec;16(4):1157-1166. doi: 10.1007/s12105-022-01484-z. Epub 2022 Aug 10.

Abstract

Background: Basal cell adenoma (BCA) and adenocarcinoma (BCAd) are two of the least frequent salivary gland tumors. We describe the largest series of these neoplasms, spanning over a period of 50 years (1970-2020), diagnosed and treated in a single Institution.

Methods: Sixty-eight cases were identified. Clinical and pathological data were collected and correlated with outcome.

Results: Forty-one BCA and 27 BCAd were identified. BCA cases had almost pristine prognosis, with only a relapse in a tumor inadequately excised. Ten patients with BCAd developed metastases, and 14 died from the disease. The 2-year and 5-year survival was of 76% and 42%.

Conclusions: The importance of adequate excision is reinforced in BCA, with no recurrences occurring when margins were negative. Contrary to previous reports, BCAd was not associated with a good prognosis. A better understanding of the genetics of these neoplasms may identify therapeutic options when dealing with inoperable or metastatic disease.

Keywords: Basal cell adenocarcinoma; Basal cell adenoma; Carcinoma ex pleomorphic adenoma; Head and neck neoplasms; Otorhinolaryngologic neoplasms; Salivary gland.

MeSH terms

  • Adenocarcinoma*
  • Adenoma*
  • Humans
  • Salivary Gland Neoplasms*